This site is intended for health professionals only

At the heart of general practice since 1960

Read the latest issue online

Gold, incentives and meh

Report this comment to a moderator

Please fill in the form below if you think a comment is unsuitable. Your comments will be sent to our moderator for review.

Report comment to moderator

Required fields.


Pregabalin patent dispute could have cost the NHS up to £54m


It is not necessarily a waste of money to prescribe trade names. If investors in drug companies do not see a decent return, where will the money come from to develop new drugs? Our government does not wish to invest in anything medical, let alone new drugs. Its tight fisted approach which forces drug companies to provide drugs to the NHS at a lower rate, is also causing drug shortages in the UK as pharmacists buy them at low NHS prices and then sell them on in other countries at a profit. We/our government has a something for nothing attitude and with our relatively small population we cannot successfully bully a global market. And when patients cannot get their meds it is the GP who has to spend time changing treatment regimes and reissuing prescriptions. The same GP that is expected to spend their (block contracted –so who cares how long it takes?) time making generic switches and arguing with patients over it. Please do not attack me over this pharmacists. I know it is not all of you. Reports suggest it is around 11%.

Posted date

22 Jan 2016

Posted time